Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
Condition(s):Infection, Human Immunodeficiency Virus; HIV InfectionsLast Updated:February 14, 2024Active, not recruiting